Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 14/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 13/20 | 0.50 |
| ▸ | PDE4A | P27815 | 13/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 11/20 | 0.50 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7414831 | 0.84 | PDE4A (0.40) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL7146146 | 0.84 | PDE4D (0.54) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL3170776 | 0.83 | PDE4B (0.53) | PDE4DPDE4BPDE4APDE4CRECQL | |
| SCHEMBL6812898 | 0.82 | PDE4D (0.56) | PDE4DPDE4BPDE4APDE4CCSNK2A1 | |
| SCHEMBL7421380 | 0.80 | PDE4B (0.51) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL20064269 | 0.79 | PDE4A (0.53) | PDE4DPDE4BPDE4APDE4CCSNK2A1 | |
| SCHEMBL5016139 | 0.79 | CA2 (0.44) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL31574673 | 0.79 | CA2 (0.44) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL5761057 | 0.76 | PDE4D (0.49) | PDE4DPDE4BPDE4APDE4CKCNH2 | |
| SCHEMBL7864303 | 0.76 | CA2 (0.44) | PDE4DPDE4BPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1481969-B1 | PIPERIDINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2011-01-19 | — | — | EP | disclosed |
| EP-1481969-B1 | PIPERIDINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2011-01-19 | — | — | EP | disclosed |
| US-7425567-B2 | Piperidine derivative compounds and drugs containing the compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-09-16 | — | — | US | disclosed |
| US-7425567-B2 | Piperidine derivative compounds and drugs containing the compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-09-16 | — | — | US | disclosed |
| US-7425567-B2 | Piperidine derivative compounds and drugs containing the compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-09-16 | — | — | US | disclosed |
| US-20050080107-A1 | Piperidine derivative compounds and drugs containing the compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-04-14 | — | — | US | disclosed |
| EP-1481969-A1 | PIPERIDINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-12-01 | — | — | EP | disclosed |
| WO-2004016596-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS PDE-IV INHIBITORS FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS | GLENMARK PHARMACEUTICALS LIMITED (US) | 2004-02-26 | — | — | WO | disclosed |
| EP-0636025-B1 | COMPOUNDS USEFUL FOR TREATING ALLERGIC OR INFLAMMATORY DISEASES | SMITHKLINE BEECHAM CORP (US) | 2001-07-18 | — | — | EP | disclosed |
| US-5811455-A | Compounds useful for treating allergic or inflammatory diseases | SMITHKLINE BEECHAM CORPORATION (US) | 1998-09-22 | — | — | US | disclosed |
| US-5631286-A | Compounds useful for treating allergic or inflammatory diseases | SMITHKLINE BEECHAM CORPORATION (US) | 1997-05-20 | — | — | US | disclosed |
| US-5449686-A | Compounds useful for treating allergic or inflammatory diseases | SMITHKLINE BEECHAM CORPORATION (US) | 1995-09-12 | — | — | US | disclosed |
| EP-0636025-A4 | COMPOUNDS USEFUL FOR TREATING ALLERGIC OR INFLAMMATORY DISEASES. | — | 1995-02-22 | — | — | EP | disclosed |
| EP-0636025-A1 | COMPOUNDS USEFUL FOR TREATING ALLERGIC OR INFLAMMATORY DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 1995-02-01 | — | — | EP | disclosed |
| WO-1993019750-A1 | COMPOUNDS USEFUL FOR TREATING ALLERGIC OR INFLAMMATORY DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 1993-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080107-A1 | Piperidine derivative compounds and drugs containing the compounds as the active ingredient | PDCD4, PDE4B, IRAK4 | PDE4D 63/4885PDE4B 2/4885PDE4A 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.